Japan Grants National Insurance Reimbursement for Optune Lua NSCLC Treatment
Japan’s Ministry of Health, Labour and Welfare approved National Health Insurance reimbursement for Optune Lua in adult patients with unresectable, advanced or recurrent non-small cell lung cancer after platinum-based chemotherapy. It is indicated with PD-1/PD-L1 inhibitors, broadening patient access to tumor treating fields in Japan’s roughly 100,000 annual NSCLC cases.
1. Reimbursement Approval
Japan’s Ministry of Health, Labour and Welfare has authorized reimbursement of Optune Lua under the National Health Insurance program for adult patients with unresectable, advanced or recurrent non-small cell lung cancer who progressed on platinum-based chemotherapy.
2. Indication and Patient Eligibility
Optune Lua is indicated for use in combination with PD-1/PD-L1 inhibitors, targeting adult NSCLC patients with advanced or recurrent disease post-platinum therapy, and will be available at qualified healthcare centers across Japan.
3. Business Impact for Novocure
National insurance coverage removes financial barriers, likely accelerating adoption of Novocure’s tumor treating fields therapy, supporting recurring device revenues and reinforcing growth prospects in one of the world’s largest oncology markets.
4. Japanese NSCLC Market Context
Non-small cell lung cancer accounts for about 85% of lung cancer cases in Japan, with roughly 100,000 new NSCLC diagnoses annually, underscoring the substantial patient pool for Optune Lua therapy adoption.